Emerging data suggest Retatrutide , a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , appears to represent a promising step forward for weight loss . Early weight lose peptide human trials have demonstrated substantial reductions in body fat , potentially outperforming current weight-loss treatments